2015 REVIEW: Korea - Mega Deals, Biosimilars, Pricing Dominate News
This article was originally published in PharmAsia News
2015 has been quite an eventful year for the South Korean pharma industry, and was marked by a string of major international licensing agreements that may be looked back on as a watershed in the industry’s attempts to shift to original R&D. If you missed any of the major news and analysis from South Korea during the year, here's your opportunity to check out PharmAsia News' view of the most important stories.
Register for our free email digests: